BEX Logo

Automated Biomarker Detection Using AI and Public Biological Databases

1. Project Objective

Build an AI-driven system that automatically identifies potential biomarkers (genes, proteins, metabolites) from large-scale biological and clinical datasets. The system will leverage multi-omics integration (genomics, transcriptomics, proteomics, metabolomics) and public repositories (GEO, TCGA, PRIDE, HMDB) to accelerate biomarker discovery. The pipeline will include automated data ingestion, feature selection, AI/ML modeling, and cross-validation to ensure reproducibility.

2. Research Questions (Hypotheses)

  1. A deep learning–based multi-omics integration model can detect candidate biomarkers with ≥ 80% predictive accuracy for selected disease phenotypes compared to baseline statistical approaches.
  2. Incorporating ontology-driven normalization (Gene Ontology, UniProt IDs, HMDB identifiers) improves biomarker selection robustness by ≥ 20% across heterogeneous datasets.
  3. Cross-dataset validation (training on TCGA, testing on GEO/PRIDE) will reduce false positives and ensure generalizability of biomarkers.
  4. Explainable AI (XAI) frameworks (e.g., SHAP, LIME) increase interpretability and researcher confidence in biomarker predictions.

3. Scope (MVP vs later phases)

MVP (3–4 months):

  • Data ingestion and preprocessing from GEO (gene expression) + TCGA (cancer genomics).
  • Initial ML pipeline (Random Forest + SVM) for feature selection and biomarker detection.
  • Output: ranked biomarker lists + confidence scores.
  • Simple visualization (heatmaps, volcano plots).

Phase 2 (6–12 months):

  • Add proteomics (PRIDE) + metabolomics (HMDB).
  • Implement deep learning (CNNs, GNNs) for multi-omics biomarker prediction.
  • Develop validation workflows across datasets.
  • Build interactive dashboard for researchers.

Phase 3 (12–24 months):

  • Incorporate clinical trial metadata (ClinicalTrials.gov, dbGaP).
  • Support reproducible workflows (biomarker reports, APIs).
  • Collaborations with labs for wet-lab validation.
  • Regulatory readiness (data governance, compliance).

4. Data Sources and Prioritization

High priority (MVP):

  • GEO (NCBI Gene Expression Omnibus – transcriptomics).
  • TCGA (The Cancer Genome Atlas – genomics + clinical).
  • DisGeNET (known gene-disease associations for benchmarking).

Medium priority (Phase 2):

  • PRIDE (proteomics).
  • HMDB / Metabolomics Workbench (metabolomics).
  • UniProt (protein function and IDs).

Later phase:

  • ClinicalTrials.gov (phenotypes, outcomes).
  • dbGaP (controlled access clinical-genomic data).
  • PDB / AlphaFold (structural biomarkers).

5. Proposed Technical Architecture (high-level)

Data Ingestion & Normalization

  • ETL pipelines for GEO, TCGA, PRIDE.
  • Normalization of identifiers (Ensembl, UniProt, HMDB).
  • Batch effect correction + missing data imputation.

Feature Selection & Indexing

  • Statistical filtering (variance, correlation with phenotype).
  • ML-based feature ranking (Random Forest feature importance).
  • Store embeddings + feature metadata in vector DB (Qdrant/Milvus).

Modeling

  • MVP: Random Forest, SVM, Gradient Boosting.
  • Phase 2: CNNs for omics data matrices, GNNs for pathway/interaction networks.
  • Ensemble learning for robustness.

Validation

  • Cross-dataset validation (e.g., biomarkers trained on TCGA tested on GEO).
  • Benchmark against curated biomarker databases.

Explainability & Visualization

  • SHAP/LIME for feature attribution.
  • Dashboard: heatmaps, volcano plots, pathway enrichment graphs.

6. Key Components / Suggested Stacks

  • Backend: Python (FastAPI, Flask).
  • ML/AI: scikit-learn, TensorFlow, PyTorch.
  • Vector DB: Qdrant or Milvus (for embeddings).
  • Conventional DB: PostgreSQL (metadata).
  • Data Processing: Apache Airflow (pipelines).
  • Visualization: React + Plotly/D3 + Cytoscape.js (pathway visualization).
  • Infra: GCP (BigQuery for omics storage, Vertex AI for ML training).

7. Workflow Example (Biomarker Detection)

User Query: “Identify biomarkers for breast cancer using TCGA expression data.”

  1. Data retrieval: TCGA RNA-seq + metadata (tumor vs normal).
  2. Preprocessing: normalization (TPM/FPKM), batch correction.
  3. Feature selection: variance filtering → ML ranking (Random Forest).
  4. Model training: classifier distinguishes tumor vs normal, outputs top-ranked genes.
  5. Validation: test against GEO breast cancer datasets.
  6. Output: ranked list of 20 candidate biomarkers with SHAP plots + links to PubMed/UniProt.

8. Evaluation / Research Metrics

  • Predictive accuracy (AUC-ROC, F1 score) of biomarker-based classifiers.
  • Precision/Recall of identified biomarkers compared to known sets.
  • Cross-dataset generalizability (% biomarkers replicated across studies).
  • Explainability metrics: user trust score (1–5 scale).
  • Latency: <1 min biomarker ranking for datasets ≤ 5k samples.

9. Suggested Timeline (MVP in 12–14 weeks)

  • Sprint 0 (1 week): Kickoff, infra setup, dataset access.
  • Sprint 1–2 (3 weeks): ETL pipelines for GEO/TCGA.
  • Sprint 3 (2 weeks): Preprocessing + normalization workflows.
  • Sprint 4 (2 weeks): Initial ML pipeline (Random Forest, SVM).
  • Sprint 5 (2 weeks): Biomarker ranking module + visualization (heatmaps).
  • Sprint 6 (2 weeks): Evaluation on GEO + documentation.
  • Sprint 7 (1–2 weeks): Demo + stakeholder feedback.

10. Minimum Recommended Team (MVP)

  • 1 Project Lead (bioinformatics/biostatistics).
  • 1 ML Engineer (feature selection, modeling).
  • 1 Data Engineer (ETL pipelines).
  • 1 Backend Developer (API, architecture).
  • 1 Frontend Developer (visualization).
  • 1 Domain Expert (molecular biology, part-time).

11. Resource / Cost Estimate (MVP)

  • Personnel (5–6 roles, 3–4 months): US$50k–100k (depending on local vs international rates).
  • Infra (cloud storage + compute): US$3k–10k (scalable).
  • APIs/tools/licenses: US$0–5k (mostly open source).
  • Total indicative MVP cost: ~US$55k–115k.

12. Risks and Mitigations

  • Heterogeneous data (omics types) → Mitigation: strict normalization + ontology mapping.
  • Overfitting to single datasets → Mitigation: cross-validation with external repositories.
  • Low interpretability → Mitigation: XAI frameworks (SHAP, LIME).
  • High compute costs → Mitigation: start with cloud credits, optimize pipelines.
  • Ethical/compliance risks → Mitigation: use only de-identified, public data.

13. Ethics and Governance

  • Use only publicly available datasets (no PHI).
  • Transparency: all biomarker results must be linked to evidence.
  • Governance board for validation before clinical applications.
  • Disclaimer: research use only, not diagnostic/clinical claims.

14. Expected Deliverables (MVP)

  • Automated pipeline: ingestion → preprocessing → ML biomarker detection.
  • Ranked biomarker lists (per disease/condition).
  • Validation report (comparison with known biomarkers).
  • Visualization dashboard (heatmaps, volcano plots).
  • Documentation + reproducibility workflows.

15. Example Output (Template)

Disease: Breast Cancer (TCGA BRCA dataset)
Top Biomarkers (genes):

  1. TP53 – mutated/overexpressed, AUC = 0.91 [TCGA, 2018]
  2. ESR1 – estrogen receptor, differential expression, AUC = 0.87 [GEO, 2020]
  3. BRCA1 – tumor suppressor, cross-validated [TCGA, GEO]
  4. HER2 (ERBB2) – amplification signature, AUC = 0.89 [TCGA, 2019]
  5. PIK3CA – mutation hotspot, predictive marker [TCGA, GEO].

Output includes confidence scores, SHAP explanation plots, and PubMed links for each.

16. Scientific Evaluation Plan

  • Benchmark pipeline against known biomarker studies (e.g., DisGeNET).
  • Compare baseline statistical methods (t-tests, DESeq2) vs AI pipeline (ML/DL).
  • Publish validation report (precision/recall of biomarker detection).
  • Collaborate with partner labs for wet-lab validation in Phase 3.

17. Extensions / Research Roadmap

  • Multi-omics integration (transcriptomics + proteomics + metabolomics).
  • Structural biomarkers (AlphaFold predictions of mutation effects).
  • Biomarker discovery for rare diseases (leveraging smaller datasets + transfer learning).
  • Clinical translation: link biomarkers to drug targets (DrugBank, PubChem).
  • Deploy as SaaS platform for partner institutions.

18. Recommended Next Steps (Immediate Action)

  1. Approve MVP scope (GEO + TCGA, transcriptomics/genomics only).
  2. Assign project team (5–6 roles).
  3. Set up cloud infra + pipelines for dataset ingestion.
  4. Build minimal ML pipeline (Random Forest, SVM).
  5. Validate first disease use case (e.g., breast cancer).